Literature DB >> 19320867

A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns.

Raymond P Goodrich1, Denise Gilmour, Nick Hovenga, Shawn D Keil.   

Abstract

BACKGROUND: Concerns over the risk of bacterial contamination of platelet products have led to implementation of bacteria culture and other screening methods. New approaches for dealing with this issue have also been proposed. STUDY DESIGN AND METHODS: A direct comparison of treatment with riboflavin and ultraviolet (UV) light (Mirasol pathogen reduction technology [PRT] system) versus bacterial culture testing (two-bottle system, 48-hour quarantine) was undertaken to compare their effectiveness. Thirteen clinically relevant bacterial organisms (20 strains) were used in this evaluation. Results were compared with spiking levels at 20 to 100 colony-forming units (CFUs) per product and at less than 20 CFUs per product.
RESULTS: At spiking levels of 20 to 100 CFUs per product, the riboflavin and UV light process demonstrated 91% effectiveness against a broad spectrum of bacteria. In comparison, the culture method demonstrated an ability to detect up to 91% of the same contaminants, when used in the two-bottle, 48-hour-to-release configuration. At lower initial titers of contaminating agents (<20 CFUs per product), the effectiveness of PRT increased to 98% whereas the culture method effectiveness decreased to 66%. Effectiveness of the culture method further decreased to 60% when a one-bottle system was used.
CONCLUSION: The results from this work suggest that the riboflavin and UV light process may provide up to 98% protection against transfusion of bacterially contaminated units at the most clinically relevant contamination levels (<20 CFUs per product). This compares favorably to the 60% to 66% effectiveness of bacterial culture testing using a 48-hour quarantine period before product release.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320867     DOI: 10.1111/j.1537-2995.2009.02126.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  13 in total

1.  Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria.

Authors:  Thomas H Müller; Thomas Montag; Axel W Seltsam
Journal:  Transfus Med Hemother       Date:  2011-07-08       Impact factor: 3.747

Review 2.  Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.

Authors:  Victor J Drew; Lassina Barro; Jerard Seghatchian; Thierry Burnouf
Journal:  Blood Transfus       Date:  2017-04-13       Impact factor: 3.443

Review 3.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

Review 4.  Pathogen inactivation technologies for cellular blood components: an update.

Authors:  Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2014-07-21       Impact factor: 3.747

5.  Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Authors:  Dragoslav Domanović; Ines Ushiro-Lumb; Veerle Compernolle; Sergio Brusin; Markus Funk; Pierre Gallian; Jørgen Georgsen; Mart Janssen; Teresa Jimenez-Marco; Folke Knutson; Giancarlo M Liumbruno; Polonca Mali; Giuseppe Marano; Yuyun Maryuningsih; Christoph Niederhauser; Constantina Politis; Simonetta Pupella; Guy Rautmann; Karmin Saadat; Imad Sandid; Ana P Sousa; Stefania Vaglio; Claudio Velati; Nicole Verdun; Miguel Vesga; Paolo Rebulla
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

6.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

7.  Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.

Authors:  Andrew P Cap; Heather F Pidcoke; Shawn D Keil; Hilary M Staples; Manu Anantpadma; Ricardo Carrion; Robert A Davey; Ashley Frazer-Abel; Audra L Taylor; Richard Gonzales; Jean L Patterson; Raymond P Goodrich
Journal:  Transfusion       Date:  2016-03       Impact factor: 3.157

8.  Evaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with Staphylococcus epidermidis: A pilot study from India.

Authors:  Kabita Chatterjee; Shamsuz Zaman; Rahul Chaurasia; Surinder Singh; Shawn D Keil; Shalini Tewari; Akanksha Bisht; Nitin Agarwal; Diptiranjan Rout; Subhash Chand; Kallol Saha
Journal:  Asian J Transfus Sci       Date:  2016 Jul-Dec

9.  A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.

Authors:  Paula F Ypma; Pieter F van der Meer; Nancy M Heddle; Joost A van Hilten; Theo Stijnen; Rutger A Middelburg; Tor Hervig; Johanna G van der Bom; Anneke Brand; Jean-Louis H Kerkhoffs
Journal:  BMJ Open       Date:  2016-01-27       Impact factor: 2.692

10.  Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination.

Authors:  Shawn D Keil; Nick Hovenga; Denise Gilmour; Susanne Marschner; Raymond Goodrich
Journal:  J Vis Exp       Date:  2015-08-24       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.